The role of <i>CYP2C19</i> genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack-Reference-Cited by-同舟云学术

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack

Published:2022-07-03 Issue:7 Volume:15 Page:811-825
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

McDermott John H¹²^ORCID,Leach Marc¹,Sen Dwaipayan³,Smith Craig J.³⁴,Newman William G.¹²,Bath Philip M.⁵⁶

Affiliation:

1. Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester, UK

2. The Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK

3. Greater Manchester Comprehensive Stroke Centre, Geoffrey Jefferson Brain Research Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK

4. Division of Cardiovascular Sciences, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

5. Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK

6. Stroke, Nottingham University Hospitals NHS Trust, Queen’s Medical Centre, Nottingham, UK

Funder

NIHR Doctoral Research

NIHR Manchester Biomedical Research Centre

the University of Manchester and the Northern Care Alliance

the University of Nottingham and NIHR HTA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link